Kailera Therapeutics, Inc. (NASDAQ:KLRA) Stock Rated “Moderate Buy” by Wall Street Analysts

Kailera Therapeutics, Inc. (NASDAQ:KLRA) has been assigned a consensus rating of “Moderate Buy” from the eight analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $42.75.

Separately, Weiss Ratings lowered shares of Kailera Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, October 6th.

Kailera Therapeutics Stock Performance

Shares of NASDAQ:KLRA opened at $10.77 on Friday. Kailera Therapeutics has a 12 month low of $9.76 and a 12 month high of $28.23. The stock’s 50-day moving average is $14.77.

Kailera Therapeutics (NASDAQ:KLRA) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.35). Analysts expect that Kailera Therapeutics will post -3.89 earnings per share for the current fiscal year.

Institutional Trading of Kailera Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of KLRA. Tidal Investments LLC bought a new position in Kailera Therapeutics in the 2nd quarter worth approximately $309,000. Mirador Capital Partners LP acquired a new position in Kailera Therapeutics during the 3rd quarter worth $666,000. Squarepoint Ops LLC acquired a new position in Kailera Therapeutics during the 2nd quarter worth $993,000. State Street Corp bought a new position in Kailera Therapeutics in the 2nd quarter valued at $19,126,000. Finally, Frazier Life Sciences Management L.P. bought a new position in Kailera Therapeutics in the 2nd quarter valued at $24,233,000.

Kailera Therapeutics Company Profile

Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and other chronic metabolic diseases. The company’s research is centered on therapies designed to address weight management and related health conditions.

Kailera’s pipeline includes ecnoglutide, an investigational, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for potential use in obesity and metabolic disorders. The company continues to advance clinical development and assess additional opportunities in the metabolic disease sector.

Kailera Therapeutics is focused primarily on research and development activities, with its programs intended for potential commercialization in international markets subject to clinical, regulatory and other approvals.